

Research Brief

Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling

Steven G. Krantz¹ and Arni S.R. Srinivasa Rao^{2,3,4}

¹Department of Mathematics, Washington University, St Louis, Missouri, ²Division of Health Economics and Modeling, Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, Georgia, ³Laboratory for Theory and Mathematical Modeling, Department of Medicine - Division of Infectious Diseases, Medical College of Georgia, Augusta, Georgia and ⁴Department of Mathematics, Augusta University, Augusta, Georgia

We estimated the underreporting of the novel coronavirus or COVID-19 as of March 9, 2020, in various countries until the first peak occurred in each country that had reported ≥ 500 cases of COVID-19 as of March 9, 2020. Our retrospective model-based estimations of underreporting (including those due to underdiagnosis) will be helpful in assessing pandemic preparedness. The ratio of reported COVID-19 cases to model-based predictions of COVID-19 for 8 major countries that had reported ≥ 500 cases up to March 9, 2020, are provided (Table 1, column I). COVID-19 reporting in France, Germany, Italy, and South Korea was comparatively much better than in other countries. For the United States, the data as of March 9, 2020, were not sufficient to provide a robust estimate.

According to Situational Report 49, released by the World Health Organization (WHO) on March 9, 2020,¹ there had been 109,000 cases of COVID-19 and 3,800 related deaths worldwide. Most of these cases ($\sim 80,700$) were from China and 8 other countries: Italy, South Korea, Iran, France, Germany, Spain, the United States, and Japan. All of these countries have reported ≥ 500 confirmed cases of COVID-19.^{1,2} However, identification of possible cases of COVID-19 is arguably more important in controlling high traffic to hospitals and emergency departments.³ Earlier models on COVID-19 did reflect the importance of data collection.⁴

Actual pandemic preparedness depends on true cases in the population, whether or not they are identified. Preventing transmission to the susceptible from these true cases depends on how well we can assess underreported and underdiagnosed situations promptly. A retrospective analysis of the data will be useful for the next epidemic but not for the current epidemic. Hence, we are proposing to use our methods, which we have been developing in recent years, to provide model-based estimates of underreporting for COVID-19 within a few weeks.

New methods using harmonic analysis and wavelets that we are developing—some of them recently accepted—will be of timely use.⁵ We propose a model-based evaluation of underreporting of coronavirus (COVID-19) in various countries using

the methods we recently developed using harmonic analysis,⁵ that is, to develop full epidemic data from partial data (using a wavelet approach). However, the current article is a preliminary analysis and modeling was done using the data available as of March 9, 2020. These data do not represent the pandemic in its entire scale; such data will need to be reevaluated when the pandemic is completely controlled. However, our predictions for underreporting as of March 9 in a couple of European countries were close to the reported number of COVID-19 cases as more cases surfaced from March 9 to March 16, 2020. Wavelets of reported cases and adjusted estimates with the underreported cases are shown in Figure 1. We also anticipate using other techniques^{5–9} to further understand the reporting once more data become available.

Data, Methods, and Models

We collected COVID-19 and population data for each country from the World Health Organization (WHO),¹ Worldometer,² and World Bank¹⁰ sources. We used population densities, proportion of the population living in urban areas, and populations delineated by 3 age groups: 0–14 years, 15–64 years, and ≥ 65 years. Furthermore, we considered daily new cases (>10) up to the first reported peak of COVID-19 cases and the corresponding date ranges for all the countries for which such data were available. This range of days varied between 8 and 16 days (Table 1). We use 2 coupled differential equations $s(t) = -\beta s(t)k(t)$ and $k(t) = \beta s(t)k(t)$, where $s(t)$ and $k(t)$ represent susceptible and infected at time t , and β is the transmission rate that is assumed to be invariant within the range of days for which the infection numbers in each country were computed. The respective β values per 100,000 thousands for the age groups 15–64 years and $\geq 65+$ years considered for various countries are as follows: China: 0.8×1.5 and $1.5, 0.75$; Italy: 1.5 and 3.0 ; Iran: 1.5 and 9.0 ; South Korea: 2.25 and 4.50 ; France: 1.50 and 3.0 ; Spain: 3.0 and 6.0 ; Germany: 1.5 and 3.0 ; and the United States: 0.75 and 1.5 . The difference between model-predicted numbers and the actual numbers reported within the range were treated as underreported, which includes underdiagnosed cases. We constructed the Meyer wavelets for the reported and adjusted data after adjusting the infected number in the population for underreporting. The Meyer wavelet is a

Author for correspondence: Arni S.R. Srinivasa Rao, E-mail: arrao@augusta.edu

Cite this article: Krantz SG and Rao ASRS. (2020). Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling. *Infection Control & Hospital Epidemiology*, 41: 857–859, <https://doi.org/10.1017/ice.2020.116>

Table 1. COVID-19 Cases, Demographics, Daily Cases, Growth Rates, and Estimated Underreporting up to March 9, 2020

| Country by No. of Confirmed Cases | Total COVID-19 Cases | Total Deaths | Population Density (2020), km ⁻² | Urban Population, (2020), % | Date Range of Daily New Cases up to the First Peak | Range of Daily New Cases up to the First Peak | Population Aged 0–14 y (2018), % | Population Aged 15–65 y (2018), % | Population Aged ≥65 y (2018), % | Model-Based Underreported & Underdiagnosed up to March 9, 2020 | No. of People Reported to the No. Infected |
|-----------------------------------|----------------------|--------------|---|-----------------------------|--|---|----------------------------------|-----------------------------------|---------------------------------|--|--|
| China | 80,761 | 3,136 | 153 | 61 | Jan 22–Feb 4 | 259–3,884 | 17.9 | 71.2 | 10.9 | 12.03–89.2 million | 1 in 149 to 1 in 1,104 |
| Italy | 10,149 | 631 | 206 | 69 | Feb 22–Mar 9 | 58–1,797 | 13.3 | 64.0 | 22.7 | 30,223 | 1 in 4 reported |
| Iran | 8,042 | 291 | 52 | 76 | Feb 21–Mar 6 | 13–1,234 | 24.5 | 69.3 | 6.2 | 266,213 | 1 in 34 reported |
| South Korea | 7,513 | 58 | 527 | 82 | Feb 23–Mar 3 | 27–851 | 13.0 | 72.6 | 14.4 | 18,809 | 1 in 4 reported |
| France | 1,784 | 33 | 119 | 82 | Feb 27–Mar 7 | 20–296 | 18.0 | 62.0 | 20.0 | 7,931 | 1 in 5 reported |
| Spain | 1,690 | 35 | 94 | 80 | Feb 27–Mar 9 | 12–557 | 14.7 | 66.0 | 19.3 | 87,405 | 1 in 53 reported |
| Germany | 1,458 | 2 | 240 | 76 | Feb 27–Mar 5 | 22–283 | 13.6 | 65.0 | 21.4 | 2,277 | 1 in 3 reported |
| United States | 874 | 28 | 36 | 83 | Mar 2–Mar 12 | 25–1,652 | 18.7 | 65.5 | 15.8 | 1.21 million (insufficient data) | 1 in 406 reported (insufficient data) |




Figure 1. Meyer wavelets for various countries for reported (dashed lines) and adjusted data after adjusting for under-reporting listed in the Table 1.

differentiable function, $\psi(\omega)$, which is infinitely differentiable in the domain with a function u as follows:

$$\psi(\omega) = \begin{cases} \frac{1}{\sqrt{2\pi}} \sin\left(\frac{\pi}{2} u\left(\frac{3|\omega|}{2\pi} - 1\right)\right) e^{\frac{i\omega}{2}} & \text{if } 2\pi/3 \leq |\omega| \leq 4\pi/3 \\ \frac{1}{\sqrt{2\pi}} \cos\left(\frac{\pi}{2} u\left(\frac{3|\omega|}{2\pi} - 1\right)\right) e^{\frac{i\omega}{2}} & \text{if } 4\pi/3 \leq |\omega| \leq 8\pi/3 \\ 0 & \text{otherwise} \end{cases}$$

Here, $u(x) = 0$ for $x \leq 0$, $u(x) = x$ for $x \in (0, 1)$, and $u(x) = 1$ for $x \geq 1$. For further details, please refer to Krantz et al⁵ and Krantz.⁹ As of March 16, 2020, we did not have enough data on COVID-19 transmissibility rates from infected to uninfected persons based on migration of populations to construct country-wide networks. We also had no clear idea of the duration that SARS-CoV-2 virus remains active on nonliving surfaces such as plastics, metals, paper, etc; thus, we did not consider the interaction

between humans and nonliving surfaces. Mathematical modeling can be made more complex by adding more parameters, but caution is necessary to ensure that these studies are well designed and that these parameters use readily available, scientifically collected data. Once we obtain more data on the duration of COVID-19 living on nonliving surfaces, we can build more complex models with more parameters.

Acknowledgments. We thank the journal's Editor-in-Chief, Associate Editor (Handling), and the Statistical Consultant for their constructive comments.

Financial support. No financial support was provided relevant to this article.


Conflicts of interest. All authors report no conflicts of interest relevant to this article.

Authors contributions. Both the authors contributed in writing. ASRS Rao designed the study, developed the methods, collected data, performed analysis, computing, wrote the first draft. SG Krantz designed the study, contributed in writing, performed analysis, editing the draft.

References

1. WHO situational report-49. World Health Organization website. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200309-sitrep-49-covid-19.pdf?sfvrsn=70dabe61_4. Published 2020. Accessed on March 9, 2020.
2. Coronavirus. Worldometer website. <https://www.worldometers.info/coronavirus/#countries>. Published 2020. Accessed on March 11, 2020.
3. Rao ASRS, Vazquez JA. Identification of COVID-19 can be quicker through artificial intelligence framework using a mobile phone-based survey in the populations when cities and towns are under quarantine. *Infect Control Hosp Epidemiol* 2020 [Epub ahead of print]. doi:10.1017/ice.2020.61
4. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020;395:689–697.
5. Krantz SG, Polyakov PG, Rao ASRS. True epidemic growth construction through harmonic analysis. *J Theoret Biol* 2020;494:110243. doi:10.1016/j.jtbi.2020.110243.
6. Rao ASRS. Understanding theoretically the impact of reporting of disease cases in epidemiology. *J Theoret Biol* 2012;302:89–95.
7. Atkins Katherine E, Wenzel Natasha S, Ndeffo-Mbah Martial, et al. Underreporting and case fatality estimates for emerging epidemics. *BMJ* 2015;350:h1115.
8. Gamado KM, Streftaris G, Zachary S. Modelling underreporting in epidemics. *J Math Biol* 2014;69:737–765.
9. Krantz SG. *A Panorama of Harmonic Analysis. The Carus Mathematical Monographs*, No. 27. Washington, DC: Mathematical Association of America; 1999.
10. The World Bank Open Data website. <https://data.worldbank.org/>. Accessed March 11, 2020.

Utility of retesting for diagnosis of SARS-CoV-2/COVID-19 in hospitalized patients: Impact of the interval between tests

Michelle E. Doll MD, MPH , Rachel Pryor RN, MPH, Dorothy Mackey BFA, Christopher D. Doern PhD, Alexandra Bryson PhD, Pamela Bailey DO, Kaila Cooper RN, MSN, CIC, Emily Godbout DO, MPH, Michael P. Stevens MD, MPH and Gonzalo Bearman MD, MPH

Virginia Commonwealth University, Richmond, Virginia

Molecular testing of nasopharyngeal specimens for SARS-CoV-2 are highly specific and sensitive.^{1,2} However, SARS-CoV-2 viral shedding within the respiratory specimens of individual patients may not be dependable or consistent throughout the course of illness.^{2–5} The range of clinical presentations of COVID-19 present a diagnostic dilemma; reports of false positives⁶ add to uncertainty. Retesting of patients is increasingly requested in the setting of ongoing concern for COVID-19 after an initial negative test. Which patients should be prioritized for retesting and at what time interval are currently unclear.

Methods

All patients admitted to a tertiary medical center with clinical concern for COVID-19 were referred to a team of infectious disease

physicians for case review and testing approval. Retesting requests were largely driven by primary team concerns for false-negative initial test results. To avoid patients going off and back on isolation, an early interval retesting protocol was developed in which patients were held on isolation and retested 24 hours after the first result if they were categorized with high probability for COVID-19. Infectious disease physicians designated each patient with high or low probability based on the following clinical criteria consistent with reported literature⁷: (1) exposure to SARS-CoV-2; (2) symptoms of COVID-19, including hypoxia, respiratory or gastrointestinal symptoms, or fever; (3) leukopenia; (4) chest imaging; (5) lack of other explanatory diagnosis. Patients labeled with high probability who tested negative were held on isolation another 24 hours for retesting. Longer-interval retesting outside this protocol continued concurrently; providers could request retesting any time during the hospitalization. If approval was granted, these patients were reisolated for possible COVID-19 pending the repeat testing.

Nasopharyngeal specimens were collected by nurses who had received online training in specimen collection. On March 26, 2020, a patient tested negative on admission to our institution, but subsequently a previously collected outpatient test was positive.

Author for correspondence: Michelle E. Doll, 1300 East Marshall Street, 2nd Floor, Room 2-071, P.O. Box 980019, Richmond, VA 23298-0019. E-mail: Michelle.Doll@vcuhealth.org

Cite this article: Doll ME, et al. (2020). Utility of retesting for diagnosis of SARS-CoV-2/COVID-19 in hospitalized patients: Impact of the interval between tests. *Infection Control & Hospital Epidemiology*, 41: 859–861, <https://doi.org/10.1017/ice.2020.224>

© The Society for Healthcare Epidemiology of America 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.